Table 5 The clinical, systemic, and laboratory characteristics of patients with primary Sjögren’s syndrome having different activities
Index | Low activity (n = 35) | Moderate–high activity (n = 20) |
|---|---|---|
ESSDAI score | 2.4 ± 1.4 | 5.2 ± 1.2 |
Age (year) | 46.6 ± 13.4 | 47.3 ± 17.5 |
Disease duration (year) | 3.8 ± 5.1 | 3.8 ± 6.1 |
Female/male | 34/1 | 19/1 |
Oral dryness (+) | 30 (85.7%) | 20 (100.0%) |
Ocular dryness (+) | 18 (51.4%) | 9 (45.0%) |
ANA (+) | 31 (88.6%) | 16 (80.0%) |
Anti-SSA (+) | 26 (74.3%) | 16 (80.0%) |
Anti-SSB (+) | 4 (11.4%) | 13 (65.0%) |
X-ray sialography (+) | 23 (65.7%) | 18 (90.0%) |
Ocular tests (+) | 23 (65.7%) | 11 (55.0%) |
Lip biopsy (+) | 13 (37.1%) | 16 (80.0%) |
Constitutional symptoms (+) | 4 (11.4%) | 12 (60.0%) |
Lymphadenopathy (+) | 5 (14.3%) | 6 (30.0%) |
Glandular injury (+) | — | — |
Articular injury (+) | 4 (11.4%) | 2 (10.0%) |
Cutaneous injury (+) | 3 (8.5%) | 3 (15.0%) |
Pulmonary injury (+) | 4 (11.4%) | 9 (45.0%) |
Renal injury (+) | 2 (5.7%) | 0 (0.0%) |
Muscular injury (+) | 4 (11.4%) | 2 (10.0%) |
Peripheral nervous system injury (+) | 1 (2.9%) | 1 (5.0%) |
Central nervous system injury (+) | 0(0.0%) | 0 (0.0%) |
Hematological test (+) | 13 (37.1%) | 15 (75.0%) |
Serum biomarkers (+) | 20 (57.1%) | 16 (80.0%) |
